NCT02321501 - Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmROS1 Gene RearrangementStage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

DRUG

Ceritinib

Given PO

DRUG

Everolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER